Your browser doesn't support javascript.
Oral cinnarizine for the treatment of COVID-19-associated chilblain-like lesions: An old drug for a new disease?
Mazzatenta, Carlo; Piccolo, Vincenzo; Argenziano, Giuseppe; Bassi, Andrea.
  • Mazzatenta C; Division of Dermatology, UO Dermatologia- Azienda USL Toscana Nord Ovest, Lucca, Italy.
  • Piccolo V; Dermatology Unit, University of Campania, Naples, Italy.
  • Argenziano G; Dermatology Unit, University of Campania, Naples, Italy.
  • Bassi A; Division of Dermatology, UO Dermatologia- Azienda USL Toscana Nord Ovest, Lucca, Italy.
Dermatol Ther ; 35(5): e15365, 2022 05.
Article in English | MEDLINE | ID: covidwho-1735904
ABSTRACT
During SARS-CoV-2 pandemic, an outbreak of chilblain-like lesions has been developed, even if the relationship with the virus infection is still debated. We report the good results obtained in 12 patients with chilblain lesions and the use of oral cinnarizine, a piperazine derivative with many pharmacological properties among whom antihistaminic and calcium channel blocking activities.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chilblains / Cinnarizine / COVID-19 Drug Treatment Type of study: Diagnostic study / Observational study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15365

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chilblains / Cinnarizine / COVID-19 Drug Treatment Type of study: Diagnostic study / Observational study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15365